VivoSim Labs (VIVS) Accounts Payables (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Accounts Payables of $1.0 million for Q1 2026, down 37.9% year-over-year from $1.6 million in Q1 2025, and up 52.16% quarter-over-quarter from $671000.0 in Q4 2025.
VivoSim Labs (VIVS) Accounts Payables (2011 - 2026) Analysis & Trends
VivoSim Labs' Accounts Payables history runs 16 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 37.9% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 37.9% YoY), while the FY2026 annual figure was $1.0 million, down 37.9% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.0 million, up from $671000.0 in the prior quarter.
- The five-year high for Accounts Payables was $1.6 million in Q1 2025, with the low at $130000.0 in Q2 2022.
- The 5-year median for Accounts Payables is $488000.0 (2023), against an average of $625705.9.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables slumped 77.47% in 2022, then soared 275.38% in 2023.
- VivoSim Labs' Accounts Payables stood at $242000.0 in 2022, then surged by 94.63% to $471000.0 in 2023, then jumped by 97.45% to $930000.0 in 2024, then declined by 27.85% to $671000.0 in 2025, then jumped by 52.16% to $1.0 million in 2026.
- Business Quant data shows VIVS's Accounts Payables at $1.0 million in Q1 2026, $671000.0 in Q4 2025, and $580000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 621,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 621,000.00 |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 671,000.00 |
| Sep 30, 2025 | 580,000.00 |
| Jun 30, 2025 | 673,000.00 |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 930,000.00 |
| Sep 30, 2024 | 419,000.00 |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 627,000.00 |
| Dec 31, 2023 | 471,000.00 |
| Sep 30, 2023 | 435,000.00 |
| Jun 30, 2023 | 488,000.00 |
| Mar 31, 2023 | 331,000.00 |
| Dec 31, 2022 | 242,000.00 |
| Sep 30, 2022 | 441,000.00 |
| Jun 30, 2022 | 130,000.00 |
| Mar 31, 2022 | 415,000.00 |
| Dec 31, 2021 | 605,000.00 |
| Sep 30, 2021 | 958,000.00 |